Abstract
The activation of the Kelchlike ECH-associated protein 1 (Keap1)-NF-E2-related factor 2 (Nrf2) pathway contributes to cancer progression in addition to oxidative stress responses. Loss-of-function Keap1 mutations were reported to activate Nrf2, leading to cancer progression. We examined the effects of Keap1 deletion in a cholangiocarcinoma mouse model using a mutant K-ras/p53 mouse. Introduction of the Keap1 deletion into liver-specific mutant K-ras/p53 expression resulted in the formation of invasive cholangiocarcinoma. Comprehensive analyses of the gene expression profiles identified broad upregulation of Nrf2-target genes such as Nqo1 and Gstm1 in the Keap1-deleted mutant K-ras/p53 expressing livers, accompanied by upregulation of cholangiocyterelated genes. Among these genes, the transcriptional factor Sox9 was highly expressed in the dysplastic bile duct. The Keap-Nrf2-Sox9 axis might serve as a novel therapeutic target for cholangiocarcinoma.
Author supplied keywords
Cite
CITATION STYLE
Nabeshima, T., Hamada, S., Taguchi, K., Tanaka, Y., Matsumoto, R., Yamamoto, M., & Masamune, A. (2020). Keap1 deletion accelerates mutant K-ras/p53-driven cholangiocarcinoma. American Journal of Physiology - Gastrointestinal and Liver Physiology, 318(3), G419–G427. https://doi.org/10.1152/ajpgi.00296.2019
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.